Ccl2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CCL2 encodes monocyte chemoattractant protein-1 (MCP-1), a key chemokine that recruits monocytes/microglia to sites of neurodegeneration. Elevated CCL2 levels are associated with AD and PD progression.
The CCL2 (Chemokine C-C Motif Ligand 2) gene encodes a pro-inflammatory chemokine that recruits monocytes and microglia to sites of injury or inflammation. CCL2 is upregulated in neurodegenerative diseases and drives neuroinflammation through microglial activation and peripheral immune cell infiltration.
This gene is involved in:
| Attribute | Value |
|---|---|
| Gene Symbol | CCL2 |
| Full Name | Chemokine (C-C Motif) Ligand 2 / Monocyte Chemoattractant Protein-1 (MCP-1) |
| Chromosome | 17 |
| Genomic Location | 17q12 |
| OMIM | 158011 |
| Ensembl ID | ENSG00000108691 |
| UniProt ID | P13500 |
The CCL2 gene encodes Chemokine (C-C Motif) Ligand 2 / Monocyte Chemoattractant Protein-1 (MCP-1), a protein expressed in various brain regions including the cerebral cortex, hippocampus, basal ganglia, and cerebellum. The protein is involved in microglial activation, neuroinflammation, and immune signaling.
CCL2 has been implicated in multiple neurodegenerative diseases:
CCL2/MCP-1 is the primary chemokine recruiting microglia to sites of neurodegeneration. Elevated CSF and brain levels correlate with disease severity in AD and PD. CCL2 drives monocyte infiltration across the BBB and promotes neuroinflammation.
CCL2/MCP-1 is the primary chemokine recruiting microglia to sites of neurodegeneration. Elevated CSF and brain levels correlate with disease severity in AD and PD. CCL2 drives monocyte infiltration across the BBB and promotes neuroinflammation.
["Alzheimer's Disease", "Parkinson's Disease", 'Multiple Sclerosis', 'Rheumatoid Arthritis']
CCL2 is expressed primarily in microglia and immune cells in the brain. Expression is elevated in AD and PD brain tissue.
| Approach | Status | Description |
|---|---|---|
| Small molecule inhibitors | Preclinical | Various compounds targeting CCL2 signaling |
| Monoclonal antibodies | Preclinical | Blocking or neutralizing antibodies |
| Gene therapy | Research | Viral vector delivery of CCL2-modulating constructs |
The study of Ccl2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
CCL2 represents a key therapeutic target in neuroinflammation:
No current clinical trials targeting CCL2 in neurodegeneration, but oncology trials exist for CCR2 antagonists.
CCL2 serves as a biomarker for neuroinflammation:
Key research areas include: